2145-53-1 Usage
Uses
Used in Pharmaceutical Industry:
4-Pyrimidinol, 5-fluoro-6-methyl(7CI,8CI) is used as a potential therapeutic agent for the treatment of various diseases, including cancer and viral infections. Its unique structure and biological activities make it a promising candidate for drug development.
Used in Agrochemical Industry:
4-Pyrimidinol, 5-fluoro-6-methyl(7CI,8CI) is used as a potential active ingredient in agrochemical products, such as pesticides or herbicides, due to its potential biological activities against pests or unwanted plants.
Used as a Research Tool:
4-Pyrimidinol, 5-fluoro-6-methyl(7CI,8CI) is used as a research tool in biological and chemical studies to investigate its properties, mechanisms of action, and potential applications in various fields. Its unique structure and potential biological activities make it valuable for scientific research and development.
Check Digit Verification of cas no
The CAS Registry Mumber 2145-53-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,1,4 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2145-53:
(6*2)+(5*1)+(4*4)+(3*5)+(2*5)+(1*3)=61
61 % 10 = 1
So 2145-53-1 is a valid CAS Registry Number.
2145-53-1Relevant academic research and scientific papers
PROCESS FOR THE PREPARATION OF VORICONAZOLE AND ANALOGUES THEREOF
-
Page/Page column 22; 23, (2014/05/07)
The present invention provides a process for preparing a compound of formula: (Formula XI and XII) (XI) (XII) wherein X, Y, Z, A, B and E are as defined herein, by reacting a compound of formula: (Formula XIII) (XIII) with a compound of formula: (Formula XIV and XV) (XIV) (XV) respectively, in the presence of a transition metal catalyst, a ligand suitable for use with 15 the catalyst and a reducing agent. The invention also provides novel intermediates.
HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS
-
Page/Page column 79, (2008/12/05)
The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
